Vanguard Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-2,071,232
| Closed | -$38.4M | – | 4565 |
|
|
2023
Q3 | $38.4M | Sell |
2,071,232
-2,622,585
| -56% | -$29.7M | ﹤0.01% | 2253 |
|
|
2023
Q2 | $51.9M | Buy |
4,693,817
+757,898
| +19% | +$10.6M | ﹤0.01% | 2164 |
|
|
2023
Q1 | $52.9M | Buy |
3,935,919
+297,984
| +8% | +$5.16M | ﹤0.01% | 2149 |
|
|
2022
Q4 | $45M | Buy |
3,637,935
+931,521
| +34% | +$13.2M | ﹤0.01% | 2235 |
|
|
2022
Q3 | $37.8M | Buy |
2,706,414
+197,255
| +8% | +$3.18M | ﹤0.01% | 2319 |
|
|
2022
Q2 | $34.7M | Buy |
2,509,159
+119,910
| +5% | +$1.92M | ﹤0.01% | 2372 |
|
|
2022
Q1 | $38.9M | Buy |
2,389,249
+417,490
| +21% | +$6.54M | ﹤0.01% | 2431 |
|
|
2021
Q4 | $32.1M | Sell |
1,971,759
-858,504
| -30% | -$14.5M | ﹤0.01% | 2594 |
|
|
2021
Q3 | $42M | Sell |
2,830,263
-542,949
| -16% | -$8.69M | ﹤0.01% | 2455 |
|
|
2021
Q2 | $67.4M | Buy |
3,373,212
+77,095
| +2% | +$1.53M | ﹤0.01% | 2210 |
|
|
2021
Q1 | $76.1M | Buy |
3,296,117
+467,162
| +17% | +$13M | ﹤0.01% | 2095 |
|
|
2020
Q4 | $69.9M | Buy |
2,828,955
+89,130
| +3% | +$2.95M | ﹤0.01% | 2029 |
|
|
2020
Q3 | $114M | Buy |
2,739,825
+254,608
| +10% | +$11.7M | ﹤0.01% | 1627 |
|
|
2020
Q2 | $119M | Buy |
2,485,217
+140,245
| +6% | +$10.8M | ﹤0.01% | 1582 |
|
|
2020
Q1 | $148M | Buy |
2,344,972
+48,534
| +2% | +$4.36M | 0.01% | 1313 |
|
|
2019
Q4 | $285M | Sell |
2,296,438
-3,442
| -0.1% | -$308K | 0.01% | 1169 |
|
|
2019
Q3 | $153M | Sell |
2,299,880
-37,742
| -2% | -$2.53M | 0.01% | 1499 |
|
|
2019
Q2 | $186M | Buy |
2,337,622
+295,674
| +14% | +$26.5M | 0.01% | 1405 |
|
|
2019
Q1 | $228M | Buy |
2,041,948
+35,326
| +2% | +$3.86M | 0.01% | 1257 |
|
|
2018
Q4 | $202M | Buy |
2,006,622
+53,691
| +3% | +$5.57M | 0.01% | 1237 |
|
|
2018
Q3 | $247M | Buy |
1,952,931
+54,038
| +3% | +$5.72M | 0.01% | 1244 |
|
|
2018
Q2 | $159M | Buy |
1,898,893
+451,758
| +31% | +$33.1M | 0.01% | 1507 |
|
|
2018
Q1 | $89M | Buy |
1,447,135
+41,404
| +3% | +$2.5M | ﹤0.01% | 1776 |
|
|
2017
Q4 | $82.1M | Buy |
1,405,731
+21,675
| +2% | +$1.37M | ﹤0.01% | 1820 |
|
|
2017
Q3 | $80.3M | Buy |
1,384,056
+55,923
| +4% | +$6.02M | ﹤0.01% | 1821 |
|
|
2017
Q2 | $161M | Buy |
1,328,133
+57,149
| +4% | +$6.62M | 0.01% | 1370 |
|
|
2017
Q1 | $144M | Buy |
1,270,984
+56,952
| +5% | +$6.65M | 0.01% | 1446 |
|
|
2016
Q4 | $132M | Buy |
1,214,032
+34,949
| +3% | +$4.16M | 0.01% | 1459 |
|
|
2016
Q3 | $194M | Buy |
1,179,083
+29,334
| +3% | +$4.62M | 0.01% | 1129 |
|
|
2016
Q2 | $164M | Buy |
1,149,749
+45,241
| +4% | +$6.6M | 0.01% | 1183 |
|
|
2016
Q1 | $142M | Buy |
1,104,508
+14,853
| +1% | +$1.75M | 0.01% | 1227 |
|
|
2015
Q4 | $163M | Buy |
1,089,655
+38,092
| +4% | +$6.45M | 0.01% | 1136 |
|
|
2015
Q3 | $174M | Buy |
1,051,563
+50,349
| +5% | +$11.1M | 0.01% | 1078 |
|
|
2015
Q2 | $242M | Buy |
1,001,214
+46,640
| +5% | +$12.4M | 0.02% | 941 |
|
|
2015
Q1 | $269M | Buy |
954,574
+200,898
| +27% | +$43.5M | 0.02% | 872 |
|
|
2014
Q4 | $118M | Buy |
753,676
+25,434
| +3% | +$4.7M | 0.01% | 1303 |
|
|
2014
Q3 | $172M | Buy |
728,242
+78,169
| +12% | +$19.9M | 0.01% | 1028 |
|
|
2014
Q2 | $154M | Buy |
650,073
+69,374
| +12% | +$18.3M | 0.01% | 1121 |
|
|
2014
Q1 | $192M | Buy |
580,699
+316,318
| +120% | +$107M | 0.02% | 945 |
|
|
2013
Q4 | $18.1M | Buy |
264,381
+73,120
| +38% | +$4.23M | ﹤0.01% | 2206 |
|
|
2013
Q3 | $13.2M | Buy |
191,261
+6,395
| +3% | +$316K | ﹤0.01% | 2271 |
|
|
2013
Q2 | $8.29M | Buy |
+184,866
| New | +$6.32M | ﹤0.01% | 2414 |
|
Vanguard Group's ICPT Position: Q4 2023 in Review
Vanguard Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 2,071,232 shares — an estimated $38.4M sold.
Vanguard Group first reported a position in ICPT in Q2 2013 and held it in 42 quarters. The position peaked at $285M in Q4 2019. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Vanguard Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Vanguard Group sold 2,071,232 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $38.4M.
- Vanguard Group first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 42 quarters.
- Vanguard Group's Intercept Pharmaceuticals, Inc. position peaked at $285M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.